259 related articles for article (PubMed ID: 32857769)
1. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.
Tamai Y; Iwasa M; Eguchi A; Shigefuku R; Sugimoto K; Hasegawa H; Takei Y
PLoS One; 2020; 15(8):e0237370. PubMed ID: 32857769
[TBL] [Abstract][Full Text] [Related]
2. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
[TBL] [Abstract][Full Text] [Related]
3. A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels.
Nakayama A; Fukuda H; Ebara M; Hamasaki H; Nakajima K; Sakurai H
Biol Pharm Bull; 2002 Apr; 25(4):426-31. PubMed ID: 11995918
[TBL] [Abstract][Full Text] [Related]
4. Relationship between copper, zinc and metallothionein in hepatocellular carcinoma and its surrounding liver parenchyma.
Ebara M; Fukuda H; Hatano R; Saisho H; Nagato Y; Suzuki K; Nakajima K; Yukawa M; Kondo F; Nakayama A; Sakurai H
J Hepatol; 2000 Sep; 33(3):415-22. PubMed ID: 11019997
[TBL] [Abstract][Full Text] [Related]
5. Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort.
Fang AP; Chen PY; Wang XY; Liu ZY; Zhang DM; Luo Y; Liao GC; Long JA; Zhong RH; Zhou ZG; Xu YJ; Xu XJ; Ling WH; Chen MS; Zhang YJ; Zhu HL
Int J Cancer; 2019 Jun; 144(11):2823-2832. PubMed ID: 30426509
[TBL] [Abstract][Full Text] [Related]
6. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of distribution patterns for copper and zinc in metallothionein and superoxide dismutase in chronic liver diseases and hepatocellular carcinoma using high-performance liquid chromatography (HPLC).
Kubo S; Fukuda H; Ebara M; Ikota N; Saisho H; Nakagawa H; Ozawa T; Yukawa M; Kato K; Satoh T; Watayo T; Sakurai H
Biol Pharm Bull; 2005 Jul; 28(7):1137-41. PubMed ID: 15997086
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors.
Franck M; Schütte K; Malfertheiner P; Link A
World J Gastroenterol; 2020 Jan; 26(1):86-96. PubMed ID: 31933516
[TBL] [Abstract][Full Text] [Related]
10. Metallothionein 2A expression and its relation to different clinical stages and grades of breast cancer in Egyptian patients.
Rezk NA; Zidan HE; Riad M; Mansy W; Mohamad SA
Gene; 2015 Oct; 571(1):17-22. PubMed ID: 26093198
[TBL] [Abstract][Full Text] [Related]
11. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
12. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
13. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
Hayashi T; Shibata M; Oe S; Miyagawa K; Honma Y; Harada M
PLoS One; 2020; 15(12):e0244370. PubMed ID: 33351844
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
[TBL] [Abstract][Full Text] [Related]
16. An improved diagnostic method for chronic hepatic disorder: analyses of metallothionein isoforms and trace metals in the liver of patients with hepatocellular carcinoma as determined by capillary zone electrophoresis and inductively coupled plasma-mass spectrometry.
Kawata T; Nakamura S; Nakayama A; Fukuda H; Ebara M; Nagamine T; Minami T; Sakurai H
Biol Pharm Bull; 2006 Mar; 29(3):403-9. PubMed ID: 16508136
[TBL] [Abstract][Full Text] [Related]
17. Roles of Copper in Hepatocarcinogenesis via the Activation of Hypoxia-Inducible Factor-1α.
Himoto T; Fujita K; Nomura T; Tani J; Miyoshi H; Morishita A; Yoneyama H; Kubota S; Haba R; Suzuki Y; Masaki T
Biol Trace Elem Res; 2016 Nov; 174(1):58-64. PubMed ID: 27121973
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.
Wang DX; Yang X; Lin JZ; Bai Y; Long JY; Yang XB; Seery S; Zhao HT
World J Gastroenterol; 2020 Aug; 26(30):4465-4478. PubMed ID: 32874058
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study.
Poo JL; Rosas-Romero R; Montemayor AC; Isoard F; Uribe M
J Gastroenterol; 2003; 38(1):45-51. PubMed ID: 12560921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
